Memel Biotech has signed an MoU with Therabest Korea to research and develop novel exosome cell therapies. In this agreement, Memel will provide integrated advanced therapy development and manufacturing services from its facility in Lithuania, whereas Therabest will provide its next-generation EiNK platform, which is designed to develop enhanced iPSC-derived immune cell therapies.
The two companies are natural collaboration partners having both gathered a wealth of cell therapy experience in product formulation, process and analytical development, process scale-up and automation, GMP manufacturing, validation and logistics. This is complemented by up-to-date knowhow of regulatory approval demands and processes in all key markets.
Memel CEO Agnė Vaitkevičienė commented: “With the help of Therabest, we will now define research projects that utilise our complementary strengths in exciting areas such as exosomes. This could also involve applying jointly for research funding.”
THERABEST CEO Pyung-Suk Ki commented: “Through the signing of this MoU, it’s anticipated that by actively harnessing the integrated infrastructure of Memel biotech's new drug development platform, THERABEST will expedite the swift progression of a diverse array of next-generation innovative products currently in development, leading them to the global clinical stage.”
The MoU is also a prime example of the growing life sciences collaboration between Lithuania and Korea and was signed in Seoul on March 25 during a highly successful Lithuanian Life Sciences delegation visit.
